ANTIHEMOPHILIC FACTOR, PEGYLATED (MW 20000) HUMAN SEQUENCE RECOMBINANT

Summary

Antihemophilic Factor, Pegylated (Mw 20000) Human Sequence Recombinant (CHEMBL4594584) is an approved unknown; indicated across 1 condition including hemophilia a.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Unknown
• Indications: 1 condition
• Clinical trials: 14

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4594584
Name	ANTIHEMOPHILIC FACTOR, PEGYLATED (MW 20000) HUMAN SEQUENCE RECOMBINANT
Type	Unknown
Max phase	4

Also known as: Adynovate, Adynovi, Pegylated recombinant factor viii, Pegylated rfviii, Rurioctocog alfa pegol

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
hemophilia A	4	MONDO:0010602	MONDO:0010602

Clinical trials

Total trials: 14.

Phase distribution

Phase	Trials
Not specified	6
PHASE3	4
PHASE1	2
PHASE4	1
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04690322	PHASE4	WITHDRAWN	POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies
NCT01736475	PHASE2/PHASE3	COMPLETED	Study Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study)
NCT02210091	PHASE3	COMPLETED	BAX 855 Pediatric Study
NCT02585960	PHASE3	COMPLETED	BAX 855 PK-guided Dosing
NCT02615691	PHASE3	COMPLETED	A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A
NCT05707351	PHASE3	COMPLETED	A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A
NCT01599819	PHASE1	COMPLETED	BAX 855 Dose-Escalation Safety Study
NCT05042440	PHASE1	COMPLETED	Pharmacokinetic Assessment of Standard Half-Life (SHL) FVIII, Extended Half-Life (EHL) FVIII, and Efanesoctocog Alfa (BIVV001) in Severe Hemophilia A
NCT04158934	Not specified	ACTIVE_NOT_RECRUITING	A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A
NCT02078427	Not specified	COMPLETED	ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD)
NCT03006965	Not specified	COMPLETED	Pharmacokinetic Characterization of the Hemophilia A Population in Spain Using myPKFiT®
NCT03169972	Not specified	COMPLETED	ADYNOVATE Drug Use-Results Survey
NCT03824522	Not specified	COMPLETED	Post Marketing Surveillance Study for ADYNOVATE in South Korea
NCT04941898	Not specified	COMPLETED	A Study of TAK-660 in Surgical Procedures for People With Hemophilia A.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).